4 ms·
The flip side would be more money available for the institutions that actually create new medicines. I'm not saying it's a better tradeoff, just that it's not s
by phyller 8y ago
The flip side would be more money available for the institutions that actually create new medicines. I'm not saying it's a better tradeoff, just that it's not so single dimensional.
- PakG1 8y agoI do not believe those institutions are lacking in funds for research. Even if they get more funds, they will still be incentivized to do R&D only on high-potential opportunities with high probability of product development success. Shareholders wouldn't care to let them just spend money just anywhere and waste it.
- 8note 8y agoexcept when the owners of the IP don't actually make new medicines, and instead us that money to buy more IP to charge higher prices for